Introduction Untangling the Roles of Antidepressants and Mood Stabilizers in the Treatment of Alzheimer's Disease

Two articles and a commentary in this issue underscore the need to clarify the roles of antidepressants and mood stabilizers in the treatment of Alzheimer’s disease (AD). Siddique and colleagues investigate the effects of the selective serotonin reuptake inhibitor (SSRI) citalopram on the treatment of irritability and apathy in AD. Hampel and colleagues use a biomarker strategy to investigate the potential of lithium to modify tau phosphorylation, a cardinal feature of AD pathology.